[go: up one dir, main page]

DK1183014T3 - Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse - Google Patents

Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse

Info

Publication number
DK1183014T3
DK1183014T3 DK00942044T DK00942044T DK1183014T3 DK 1183014 T3 DK1183014 T3 DK 1183014T3 DK 00942044 T DK00942044 T DK 00942044T DK 00942044 T DK00942044 T DK 00942044T DK 1183014 T3 DK1183014 T3 DK 1183014T3
Authority
DK
Denmark
Prior art keywords
flavored
pharmaceutical compositions
controlled release
oral pharmaceutical
release oral
Prior art date
Application number
DK00942044T
Other languages
Danish (da)
English (en)
Inventor
Roberto Villa
Massimo Pedrani
Mauro Ajani
Lorenzo Fossati
Original Assignee
Cosmo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26331662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1183014(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT1999MI001317A external-priority patent/ITMI991317A1/it
Priority claimed from IT2000MI000422A external-priority patent/IT1317871B1/it
Application filed by Cosmo Spa filed Critical Cosmo Spa
Application granted granted Critical
Publication of DK1183014T3 publication Critical patent/DK1183014T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00942044T 1999-06-14 2000-06-09 Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse DK1183014T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI001317A ITMI991317A1 (it) 1999-06-14 1999-06-14 Sistemi terapeutici a rilascio modificato per forma farmaceutiche orali
IT2000MI000422A IT1317871B1 (it) 2000-03-03 2000-03-03 Sistemi terapeutici per forme farmaceutiche orali di principi attiviaventi sfavorevoli caratteristiche organolettiche.
PCT/EP2000/005356 WO2000076478A1 (fr) 1999-06-14 2000-06-09 Compositions pharmaceutiques administrables par voie orale a liberation controlee et gout masque

Publications (1)

Publication Number Publication Date
DK1183014T3 true DK1183014T3 (da) 2004-02-09

Family

ID=26331662

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00942044T DK1183014T3 (da) 1999-06-14 2000-06-09 Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse

Country Status (17)

Country Link
US (20) US7431943B1 (fr)
EP (1) EP1183014B1 (fr)
JP (3) JP4790950B2 (fr)
CN (1) CN1173695C (fr)
AT (1) ATE251449T1 (fr)
AU (1) AU5680100A (fr)
CA (1) CA2377301C (fr)
DE (1) DE60005819T2 (fr)
DK (1) DK1183014T3 (fr)
ES (1) ES2208349T3 (fr)
HK (1) HK1046244B (fr)
MX (1) MXPA01012889A (fr)
NO (1) NO331642B1 (fr)
PT (1) PT1183014E (fr)
RU (1) RU2246293C2 (fr)
TR (1) TR200200562T2 (fr)
WO (1) WO2000076478A1 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
RU2246293C2 (ru) * 1999-06-14 2005-02-20 Космо С.П.А. Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (fr) 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
WO2003103634A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formes posologiques orales a liberation prolongee de gabapentine
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2005009432A1 (fr) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Posologie nouvelle en cas d'administration concurrente de gabapentine avec des aliments et biodisponibilite orale accrue ainsi obtenue
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
ITMI20040187A1 (it) * 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2288117B1 (es) * 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
JP2009543873A (ja) * 2006-07-19 2009-12-10 ザ、ボード、アヴ、リージェンツ、アヴ、ズィ、ユーニヴァーサティ、アヴ、テクサス、システィム 炎症性腸疾患を治療するためのリン脂質および５−アミノサリチル酸を含有する医薬品の調製
CA2663548A1 (fr) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Compositions pharmaceutiques pour administration de substances proteiques par voie buccale ou anale
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
DE102007041588A1 (de) * 2007-09-01 2009-03-05 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit Hefe
EA024147B1 (ru) * 2008-04-29 2016-08-31 Фарнекст Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
CA2734646C (fr) 2008-08-20 2016-06-28 James W. Mcginity Extrusion a chaud de multiparticules a liberation modifiee
CA2638240C (fr) * 2008-08-29 2010-02-02 Alexander Macgregor Methode de traitement des anomalies de la glycemie et des variations de la glycemie
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
HRP20170886T1 (hr) * 2009-01-12 2017-09-08 Biokier Inc. Smjesa i metoda za liječenje dijabetesa
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US20220054406A1 (en) * 2009-01-12 2022-02-24 Biokier, Inc. Composition and method for treatment of diabetes
US8945615B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945616B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
DE102009012788A1 (de) * 2009-03-13 2010-09-30 J. Rettenmaier & Söhne Gmbh + Co. Kg Verpressbares Tablettenmaterial mit ölhaltigem Wirkstoff, Tablette sowie Verfahren und Vorrichtung zu deren Herstellung
HRP20150110T1 (hr) 2009-05-18 2015-05-08 Sigmoid Pharma Limited Kompozicija koja sadrži uljne kapljice
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2440210A4 (fr) 2009-06-12 2014-01-29 Meritage Pharma Inc Procédés de traitement de troubles gastro-intestinaux
JP2013502452A (ja) * 2009-08-24 2013-01-24 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ オチロニウムの直接圧縮錠
MX2012003459A (es) 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
WO2011057131A1 (fr) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Hydrogels à base de polysaccharide
CN107033368A (zh) 2009-11-09 2017-08-11 聚光灯技术合伙有限责任公司 碎裂水凝胶
IT1398643B1 (it) * 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
WO2011143511A2 (fr) 2010-05-12 2011-11-17 Columbia University Procédés de production de cellules entéroendocrines capables de fabriquer et de sécréter de l'insuline
WO2011154975A2 (fr) 2010-06-08 2011-12-15 Cadila Healthcare Limited Compositions pharmaceutiques de metformine
WO2012013495A1 (fr) 2010-07-29 2012-02-02 Cosmo Technologies Ltd. Compositions pharmaceutiques et/ou alimentaires à base d'acides gras à chaîne courte
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
EP2446877A1 (fr) * 2010-10-29 2012-05-02 Roquette Frères Matrice à base de dérivés d'amidon modifié pour cibler le côlon
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
MX2013012720A (es) * 2011-05-02 2013-12-06 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
AT511581A1 (de) * 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
CA2854054C (fr) * 2011-12-02 2020-05-12 Pegasus Laboratories, Inc. Compositions a liberation prolongee a base de lipides amphipathiques
WO2013120881A1 (fr) 2012-02-13 2013-08-22 Cosmo Technologies Limited Procédé de traitement de maladies intestinales présentant au moins une composante inflammatoire
ES2692068T3 (es) 2012-03-29 2018-11-30 Therabiome, Llc Formulaciones para vacunación oral específica a sitio gastrointestinal activas sobre el íleo y el apéndice
EP2722058A1 (fr) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Composition orale solide contenant des colorants convenant pour diagnostic endoscopique
EP2943183A1 (fr) * 2013-01-14 2015-11-18 InFirst Healthcare Limited Compositions et procédés destinés au traitement de la douleur aiguë
PL3795141T3 (pl) * 2013-01-14 2025-11-12 Infirst Healthcare Limited Kompozycje w postaci roztworu stałego
HK1218621A1 (zh) * 2013-02-04 2017-03-03 Infirst Healthcare Limited 用於治疗慢性炎症和炎性疾病的组合物及方法
JP6464142B2 (ja) 2013-03-14 2019-02-06 セラバイオーム，エルエルシー プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
US9240075B2 (en) 2013-03-15 2016-01-19 Daqri, Llc Campaign optimization for experience content dataset
CN103417507B (zh) * 2013-08-23 2015-12-02 王显著 布地奈德药物组合物
US20150073057A1 (en) 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
ITMI20131578A1 (it) * 2013-09-25 2015-03-26 Giellepi S P A Sostanza e formulazione per il trattamento delle malattie infiammatorie croniche intestinali
IN2013MU03373A (fr) * 2013-10-25 2015-07-17 Cadila Healthcare Ltd
WO2015071812A1 (fr) 2013-11-18 2015-05-21 Wockhardt Limited Composition à libération modifiée orale et solide comprenant du budésonide ou un sel de celui-ci
GB2525227B (en) 2014-04-16 2016-09-14 Jaguar Land Rover Ltd Bumper assembly method and apparatus
CA2985344A1 (fr) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York L'inhibition de l'expression de la serotonine dans des cellules enteroendocrines intestinales provoque leur conversion en cellules positives pour l'insuline
EP3006453A1 (fr) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters et 17alpha, 21-diesters de cortexolone pour utilisation dans le traitement de tumeurs
CN104523717A (zh) * 2015-01-06 2015-04-22 西南大学 西甲硅油奥替溴铵咀嚼片及其制备方法
WO2017058881A1 (fr) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Utilisation de la pentoxifylline sous thérapies de blocage des points de contrôle immunitaires pour le traitement du mélanome
US20200061212A1 (en) 2016-11-28 2020-02-27 Cosmo Technologies Ltd. Solid oral composition containing dyes
WO2018129079A1 (fr) * 2017-01-03 2018-07-12 Thermolife International, Llc Procédé pour isoler de la théacrine et composition comprenant de la théacrine
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
AR114140A1 (es) 2017-11-10 2020-07-29 Cosmo Technologies Ltd Composiciones orales de rifamicina sv
EP3501503A1 (fr) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Composition pour administration solide
EP3613414A1 (fr) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Granulés à structure multicouche permettant la libération retardée de la substance active dans le colon distal
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法
EP4346858A4 (fr) * 2021-06-01 2025-06-18 NBI Biosciences Pvt Ltd Formulation d'administration de médicament intestinal oral à déclenchement microbien et son procédé de préparation
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133863A (en) 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3800051A (en) 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
WO1985003436A1 (fr) 1984-02-10 1985-08-15 A/S Alfred Benzon Formulation de dosage d'unites multiples enrobees a liberation par diffusion
US4608248A (en) 1985-11-08 1986-08-26 Warner-Lambert Company Process for time-controlled release of active ingredients
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL92343A0 (en) 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
WO1992016214A1 (fr) 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. Utilisation d'acide 5-aminosalicylique pour le traitement de colon irritable - type ou phase diarrheique (ibs-d)
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
TW209174B (fr) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE69233130T2 (de) 1991-05-28 2005-06-02 Mcneil-Ppc, Inc. Kaubare zusammensetzung zur arzneimittelfreisetzung
US5534501A (en) * 1991-06-04 1996-07-09 A Et S Biovecteurs Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
IT1250654B (it) 1991-07-08 1995-04-21 Farcon Ag Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
WO1995016451A1 (fr) 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
GB9224855D0 (en) 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
BR9307746A (pt) * 1993-01-08 1995-11-14 Astra Ab Derivados de esteróides especificos para otratamento de cólon e ileo
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0621032B1 (fr) * 1993-04-23 2000-08-09 Novartis AG Dispositif d'administration de médicaments à libération contrôlée
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
CA2186750C (fr) * 1994-03-30 2008-08-05 Jens Hansen Utilisation d'esters d'acides gras comme substances bioadherentes
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
RU2155605C2 (ru) 1994-04-22 2000-09-10 Яманоути Фармасьютикал Ко., Лтд. Система, выделяющая лекарство, специфичное в отношении толстой кишки
JPH10500944A (ja) * 1994-05-05 1998-01-27 メルク シヤープ エンド ドーム リミテツド モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
CN1088584C (zh) 1996-08-02 2002-08-07 久光制药株式会社 口服制剂用胶囊及口服胶囊制剂
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE69818607T2 (de) 1997-05-30 2004-07-29 Osmotica Corp. Mehrlagige osmosevorrichtung
NZ503086A (en) * 1997-08-29 2002-03-01 Upjohn Co An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes
DE29717252U1 (de) 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US5965167A (en) 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6239120B1 (en) * 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
CA2274943A1 (fr) 1998-06-17 1999-12-17 Stephen L. Wolman Compositions pour le traitement et la prevention de maladies inflammatoires du tractus gastro-intestinal, et methodes et utilisations connexes
DE19849737A1 (de) 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
RU2246293C2 (ru) 1999-06-14 2005-02-20 Космо С.П.А. Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
US6363635B1 (en) 1999-10-22 2002-04-02 Superior Bronze Corporation Of America Memorial markers and method for producing the same
JP4159217B2 (ja) 1999-12-15 2008-10-01 花王株式会社 皮膚外用剤
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
US20060188563A1 (en) 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
US7715806B2 (en) 2004-10-06 2010-05-11 Broadcom Corporation Method and system for diversity processing including using dedicated pilot method for closed loop
US20100305076A1 (en) 2006-09-13 2010-12-02 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis
JP5132416B2 (ja) 2008-05-08 2013-01-30 キヤノン株式会社 画像処理装置およびその制御方法
ES2358158T3 (es) 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
EP2298321A1 (fr) 2009-08-26 2011-03-23 Nordic Pharma Nouvelles compositions pharmaceutiques pour le traitement de maladies intestinales inflammatoires
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
US8787888B2 (en) * 2012-08-29 2014-07-22 Facebook, Inc. Sharing location information during a communication session

Also Published As

Publication number Publication date
CA2377301A1 (fr) 2000-12-21
US20090011010A1 (en) 2009-01-08
AU5680100A (en) 2001-01-02
CN1173695C (zh) 2004-11-03
US10143698B2 (en) 2018-12-04
US7410651B2 (en) 2008-08-12
TR200200562T2 (tr) 2002-05-21
US20060159749A1 (en) 2006-07-20
US20190134061A1 (en) 2019-05-09
JP2003501457A (ja) 2003-01-14
PT1183014E (pt) 2003-12-31
US20140302143A1 (en) 2014-10-09
HK1046244A1 (en) 2003-01-03
US20120321710A1 (en) 2012-12-20
US20190015428A1 (en) 2019-01-17
US8293273B2 (en) 2012-10-23
US7410652B2 (en) 2008-08-12
NO20016108D0 (no) 2001-12-14
US9320716B2 (en) 2016-04-26
ATE251449T1 (de) 2003-10-15
US20170304322A1 (en) 2017-10-26
WO2000076478A1 (fr) 2000-12-21
USRE43799E1 (en) 2012-11-13
DE60005819T2 (de) 2004-05-06
EP1183014B1 (fr) 2003-10-08
US9532954B2 (en) 2017-01-03
US10105374B2 (en) 2018-10-23
US20120021053A1 (en) 2012-01-26
US20060134208A1 (en) 2006-06-22
JP2011102310A (ja) 2011-05-26
ES2208349T3 (es) 2004-06-16
JP5279851B2 (ja) 2013-09-04
US8029823B2 (en) 2011-10-04
US10064878B2 (en) 2018-09-04
JP2011102311A (ja) 2011-05-26
US20170143741A1 (en) 2017-05-25
DE60005819D1 (de) 2003-11-13
EP1183014A1 (fr) 2002-03-06
MXPA01012889A (es) 2003-06-24
US20140302139A1 (en) 2014-10-09
RU2246293C2 (ru) 2005-02-20
US20130053360A1 (en) 2013-02-28
US20150056279A1 (en) 2015-02-26
JP4790950B2 (ja) 2011-10-12
NO20016108L (no) 2002-01-24
CN1355693A (zh) 2002-06-26
US20120220559A1 (en) 2012-08-30
US8784888B2 (en) 2014-07-22
HK1046244B (zh) 2005-06-03
NO331642B1 (no) 2012-02-13
CA2377301C (fr) 2009-05-12
US20190022112A1 (en) 2019-01-24
JP5279850B2 (ja) 2013-09-04
US7431943B1 (en) 2008-10-07
US20120213850A1 (en) 2012-08-23
US20130022679A1 (en) 2013-01-24
US20170304323A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
DZ2685A1 (fr) Formulation pharmaceutique orale à libération prolongée.
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
WO2000041681A3 (fr) FORMULATIONS DE MEDICAMENTS CONTENANT UN OPIOIDE ET UN α-AGONISTE
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
WO2001041737A3 (fr) Forme de dosage oral solide
ITRM20000667A0 (it) Compressa matrice che permette la liberazione prolungata di trimetazidina dopo somministrazione per via orale.
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
YU8701A (sh) Nova oralna kompozicija
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2002034240A3 (fr) Formulations a liberation retardee et prolongee et procede d'utilisation
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
JP2006527741A5 (fr)
MA26604A1 (fr) Compositions pharmaceutiques.